Hikma Pharmaceuticals PLC (HIK.L)
1,100.00GBp
11:01am EDT
-12.00p (-1.08%)
1,112.00p
1,114.00p
1,117.00p
1,096.00p
225,307
238,012
1,127.00p
696.00p
About
Overall
| Beta: | 0.70 |
| Market Cap (Mil.): | £2,213.90 |
| Shares Outstanding (Mil.): | 197.94 |
| Dividend: | 6.56 |
| Yield (%): | 0.94 |
Financials
| HIK.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 33.44 | 38.06 | 37.87 |
| EPS (TTM): | 0.33 | -- | -- |
| ROI: | 8.89 | 19.42 | 18.70 |
| ROE: | 12.47 | 20.10 | 19.53 |
UPDATE 1-Hikma raises full-year revenue forecast again
* Shares up as much as 9 pct (Adds analysts' comments, details; updates share movement)
BRIEF-Hikma signs marketing deal with Theravance
LONDON, July 1 - Hikma Pharmaceuticals PLC : * Signing of an exclusive commercialisation agreement with theravance, inc for
Hikma expects revenue to rise 13 pct in 2013
May 16 - Hikma Pharmaceuticals Plc raised its full-year revenue forecast, saying its generic antibiotic doxycycline was generating revenue ahead of its expectations.
BRIEF-Hikma Pharmaceutical expects group revenue to grow by around 13% in 2013
LONDON, May 16 - Hikma Pharmaceuticals PLC : * Hikma pharmaceutical - interim management statement * Branded and injectables businesses are on track to meet our current FY
Hikma Pharma rejects sale of injectables business
LONDON, April 17 - Hikma Pharmaceuticals said on Wednesday it would keep its fast-growing injectables business after weighing up a number of unsolicited approaches for the unit.
BRIEF-Hikma to keep global injectables business
LONDON, April 17 - Hikma Pharmaceuticals PLC : * CORRECTED-HIKMA PHARMACEUTICALS PLC - DETERMINED THAT GLOBAL
Injectables business boosts Hikma Pharma's profit
March 13 - Hikma Pharmaceuticals Plc reported a 19 percent rise in full-year profit, helped by strong growth in its lucrative injectables business, which has drawn interest from several bidders.
BRIEF-Hikma Pharmaceuticals expects revenue to grow 10 percent in 2013
LONDON, March 13 - Hikma Pharmaceuticals PLC : * Auto alert - Hikma Pharmaceuticals Plc final dividend 0.10 usd per
UPDATE 2-Hikma eyes options for injectables business, shares rise
* Says got expressions of interest for injectables business
Hikma says considering strategic options for injectables business
March 1 - Hikma Pharmaceuticals Plc said it reviewing options for its injectables business.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

